The Food and Drug Administration (FDA) has recently launched a new cholesterol lowering drug that promises to deliver better results than any other product. Alirocumab, or as it is popularly known by the brand name, Praluent, has been launched in the form of an injectable drug by the pharmaceutical giants Regeneron and Sanofi. It has been developed as part of an entirely new class of drugs, introduced as PCSK9 inhibitors.
The main function of this new cholesterol lowering drug is to refine the process of the liver by making it more efficient to eliminate bad cholesterol or LDL from the body. At the launch of the drug, it was approved for any patient who suffers from HeFh (heterozygous familial hypercholesterolemia).
It is a medical condition which increases the level of LDL cholesterol in the body. It causes a number of problems that might lead to fatal health condition, such as stroke or heart attack. It is also an ideal medication for those who have previously suffered from any cardiovascular condition associated with cholesterol level, such as continuous heartache or stroke.
Praluent is specifically manufactured for people who have a history of clinical illness or fluctuations in the level of cholesterol. Professor of Cardiology at the Mount Sinai Hospital in NYC, Dr. Donald Smith states it is ideal for people whose LDL is above the normal level. This is because people with high levels of bad cholesterol are more susceptible to developing potentially serious diseases.
There are many patients who have still not been treated as they should be and this is mainly due to the lack of an effective medication. The launch of Praluent as an effective cholesterol lowering drug has given hope to both the patients and doctors. It is a viable option for many of those whose body doesn’t respond to the medication that are already available in the market. Besides this, not all cholesterol lowering drugs are safe for consumption for everyone.
Doctors leading the research on Praluent claim this new drug can be more beneficial and approved for a broader group of patients suffering from any condition related to high LDL levels. The product will take a few more weeks to reach the market. The price will be variable, depending on the insurance plan for patients, whereas for wholesalers it will cost $1,200 per month. It is expected to cost more than a regular statin.
Conclusively, this new drug can be effective for many but it’s not free from the side-effects, including swelling or itching. Cold and flu are some of the other common symptoms that can result from daily consumption.